45 results about "Total dose" patented technology

Systems and methods are provided for facilitating the dispensing of a medication from a dispensing station. An order is received and includes the medication and a total dosage for the medication to be dispensed. The medication is mapped to a table that stores a list of a plurality of medications that are available for dispensing at one or more dispensing stations at different physical locations. Each of the plurality of medications are stored in the table with a corresponding unit usable to formulate a dosage. A particular medication is identified in the plurality of medications in the table that corresponds to the medication of the order. The particular medication also corresponds to the total dosage based on the corresponding unit in the table associated with the particular medication. An instruction is communicated to the one or more dispensing stations to dispense the particular medication.

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

Provided herein is a method of reducing exogenous insulin use. In some embodiments, such methods may comprise administering tilizumab to a subject in need thereof at a total dose of from about 9000 [mu] g / m2 to about 14000 [mu] g / m2 for a course of 12 to 14 days.

This invention belongs to the field of animal model construction technology, specifically relating to a mouse immunosuppressive model that maintains a long-term immunosuppressive state, its construction method, and its application. This invention establishes a stable immunosuppressive state model with reduced neutrophil count and no significant decrease in erythrocyte count by administering different doses of immunosuppressants (10-50 mg / kg body weight) to Balb / c mice via a combination of "reduced total dose + multiple gavage administration + satellite monitoring." The method for constructing this mouse immunosuppressive model reduces drug usage, controls neutrophil count rebound, establishes a stable model of reduced neutrophil count, and avoids deep bone marrow suppression (i.e., does not cause an uncontrollable decrease in erythrocyte or platelet count), which is beneficial for long-term experimental conduct and drug evaluation.

Disclosed are a system, techniques and processes for monitoring and modifying a drug treatment regimen when a user partakes in a ketogenic diet. The disclosed system obtains ketone level measurements of a user and indicates a user's adherence to the ketogenic diet as well as modifying a user's total daily dosage of a drug based on the user's following the ketogenic diet.

The invention relates to the technical field of aerospace, in particular to a space charged particle total dose detection device which comprises a packaging shell and an integrated acquisition circuit. The packaging shell comprises a main shell (1), a bottom cover plate (2) and a trapezoidal channel (3); a first opening is formed in the bottom of the main shell (1), and a second opening is formed in the top; the bottom cover plate (2) covers the first opening and is connected with the main shell (1); the trapezoidal channel (3) serves as an incident channel of particles, a third opening connected with the second opening is formed in the top of the trapezoidal channel, and a fourth opening is formed in the bottom of the trapezoidal channel and extends into the packaging shell; the integrated acquisition circuit is fixed in the packaging shell and comprises a circuit board and a dose sensitive sensor; the circuit board is provided with a first surface facing the trapezoidal channel (3) and a second surface opposite to the trapezoidal channel (3); and the dose sensitive sensor is used for detecting the total dose of the charged particles, is arranged on the first surface of the circuit board, is positioned under the fourth opening and is used for receiving the charged particles to be detected.

A radiotherapy planning apparatus includes processing circuitry. The processing circuitry obtains a medical image relating to a patient. The processing circuitry obtains number of beams and beam directions of a plurality of radiation beams applied substantially simultaneously to an irradiation area of the patient. The processing circuitry generates a total dose rate distribution which is a spatial distribution of total values of predicted dose rates of the radiation beams to be applied to the patient, based on the medical image and the number and the direction of the radiation beams.

Provided herein are methods of treating type 1 diabetes mellitus (T1D). Such methods may comprise administering tilizumab to a subject in need thereof at intervals of about 3 months to about 12 months at a total dose greater than about 9000 [mu] g / m2 for a first 12-day course of treatment and tilizumab at a total dose greater than about 9000 [mu] g / m2 for a second 12-day course of treatment.

The present invention provides methods, compositions, devices, and kits for treating cystinuria or related disorders, in which tiopronin is administered to a patient according to a modified-release strategy that releases tiopronin in critically-spaced, repeated pulses over time, to provide lower peak plasma levels but consistently higher urine levels of the drug for binding cystine. In particular, use of the present modified-release formulations and systems reduce side effects of tiopronin, thereby increasing patient compliance and quality of life, as well as achieving efficacy with less frequent administrations and / or lower total dosages.

The invention discloses a COTS device total dose irradiation assurance grading method based on in-orbit application scene classification, and the method comprises the steps: firstly carrying out the key grade division of single machines, including I-grade single machines, II-grade single machines and III-grade single machines, then carrying out the COTS device total dose irradiation assurance grade division, and finally carrying out the classification based on application scenes. And enabling different stand-alone grades to correspond to different irradiation assurance grades, and carrying out a total dose irradiation evaluation test. The application-based COTS device total dose irradiation guarantee method is formed according to the characteristics of different COTS devices, the purposes of agility, high efficiency and scientific reduction of test cost are achieved, the use cost of components is reduced, meanwhile, the reliability of on-orbit application is ensured, the problem that the COTS device total dose irradiation evaluation test is expensive is solved, and the method is suitable for popularization and application. The defect that an existing irradiation test method is scientific in process and cost reduction and has no specific implementation path is overcome.

A method for incorporating an extended bolus signal is disclosed. The method includes determining a target dose amount of medicament to deliver for a control cycle. The method also includes obtaining data related to an extended bolus. The method further includes determining an additional medicament amount to deliver during the control cycle corresponding to the extended bolus. The method yet further includes determining a total medicament delivery amount for the control cycle corresponding to the target dose amount and the additional medicament amount. The method still further includes sending a command to a delivery mechanism to cause delivery of the total medicament delivery amount for the control cycle.

The application belongs to the technical field of three-dimensional integrated circuits, and discloses a through-silicon via link total dose effect evaluation method, equipment and medium based on an equivalent circuit model, wherein the method comprises the following steps: establishing a total dose equivalent circuit topology structure according to a through-silicon via structure; determining a parasitic electric parameter calculation equation in the total dose effect equivalent circuit; calculating the value of the electric parameter under normal conditions, and comparing the S parameter obtained through simulation calculation with the actually measured S parameter to verify the total dose effect equivalent circuit model; optimizing the design, extracting the electric parameter in the equivalent circuit under different radiation dose conditions; extracting the electric parameter change curve with the radiation dose; fitting the equation of the material attribute change with the radiation dose; and predicting the S parameter of the through-silicon via link at any radiation dose point. The equipment and medium are used for realizing the through-silicon via link total dose effect evaluation method based on the equivalent circuit model. The evaluation factors are comprehensive, the actual irradiation conditions can be better matched, and the performance of the through-silicon via link under the actual radiation conditions can be more accurately simulated.

One or more example embodiments of the present invention relates to a dose control method for a mobile x-ray detector of a medical x-ray system, comprising generating a data packet having a time stamp of a clock of the mobile x-ray detector and a dose value; sending the data packet via a radio link from the mobile x-ray detector to an x-ray generator; receiving the data packet from the x-ray generator; comparing the time stamp with a clock of the x-ray generator and calculating a latency; and extrapolating an overall dose from the dose value, the time stamp and the latency.

A method for testing the total dose effect of a SiC MOSFET device, realizing verification of the complex total dose effect of the SiC MOSFET. The test steps sequentially comprise: testing a tested device before irradiation; performing annealing treatment on the tested device before irradiation; performing an irradiation test on the tested device; performing annealing treatment on the tested device after irradiation; performing test data analysis and processing on the tested device after irradiation. In the test process, threshold voltage shift caused by total dose radiation-induced defects and threshold voltage shift caused by near interface trap charges inherent near a SiC MOSFET interface are measured respectively, comprehensive analysis and calculation are carried out on the test result, the total dose effect resistance capability of the SiC MOSFET device can be given, and a certain guiding effect on device reinforcement is achieved.

The invention discloses a phase inverter capable of simultaneously resisting total dose and single event effect, which adopts the structural design that a main phase inverter and an auxiliary phase inverter are combined, and the main phase inverter is composed of two PMOS (P-channel Metal Oxide Semiconductor) tubes connected in series and an NMOS (N-channel Metal Oxide Semiconductor) tube. On the basis of a mode that an auxiliary phase inverter provides a level compensation signal at the NMOS source end of a main phase inverter, the high level output by the phase inverter under the total dose effect is prevented from being reduced, and transient upset of the output level of the phase inverter from high to low under the single event effect of an NMOS tube is avoided; on the basis of a double PMOS structure design mode, transient upset of the output level of the inverter from low to high caused by conduction of a PMOS tube under a single event effect is avoided. And finally, stable output of the inverter under the total dose and single-particle system effect can be realized.

The present invention discloses a drug injection device for heart failure, and key technical solutions thereof are as follows: The device includes a delivery catheter and an abutting component disposed at one end of the delivery catheter. Multiple guide holes are formed in the abutting component. A reservoir tube is slidably connected in the delivery catheter. Multiple injection needles in communication with the reservoir tube are disposed at one end of the reservoir tube close to the abutting component. The multiple injection needles are slidably inserted in the multiple guide holes respectively in one-to-one correspondence. A sealing plate is rotatably connected in an inner wall of one end of the reservoir tube close to the injection needle. The present invention has the following technical effects: By providing the reservoir tube, the present invention enables adjustment of the movable tube's extension length from the injection tube during operation. This controls the distance between the injection piston and the sealing plate, where a space volume between the injection piston and the sealing plate is a total dosage of the single-dose medication. In this way, accurate dose control is achieved for each injection.

The invention relates to a board-level ionization total dose effect irradiation test method, and belongs to the technical field of space environment engineering. The method comprises the steps of plate-level electrical parameter testing before irradiation, ionization total dose effect irradiation under a device-level bias condition, room-temperature annealing, high-temperature annealing and plate-level electrical parameter testing after ionization total dose effect irradiation. According to the invention, the technical effect of carrying out the ionization total dose effect irradiation test with high efficiency, accuracy and low cost can be realized.

The invention discloses a system and a method for measuring equivalent biological dose of targeted alpha nuclide therapy based on a voxel model. According to the system, a patient-specific three-dimensional voxel anatomical model and an activity distribution diagram are constructed through an image processing module; the intelligent energy item module calls a pre-established dose point core database according to decay characteristics of the selected alpha nuclide to generate an equivalent total dose point core; the dose calculation module performs fast convolution calculation based on the cumulative activity and the equivalent total dose point kernel to obtain a three-dimensional physical absorbed dose; the biological dose module is integrated with a micro-dose dynamic model and converts physical dose into a three-dimensional biological dose distribution diagram equivalent to conventional external radiation therapy. The technical defects that a standard model is large in error, Monte Carlo simulation consumes time, depends on multi-time-point dynamic imaging, and the physical dose cannot reflect the alpha particle biological effect are overcome, efficient, accurate and clinically practical individualized biological dose evaluation is achieved, and the accuracy and safety of a treatment scheme are remarkably improved.

There is disclosed compositions and methods for treating and preventing Acute Respiratory Distress Syndrome (ARDS) including ARDS caused by viral respiratory disease of zoonotic origin such as coronaviruses. The present disclosure is based on a surprising discovery of significant efficacy in an acute lung injury model using intrapulmonary lipopolysaccharide (LPS) challenge in female CD-I mice. Based on these data, the test compound, denatonium acetate monohydrate (DA) (1) treats or prevents ARDS and, (2) treats severe acute respiratory syndrome (SARS) caused by a coronavirus. Therefore, the data achieved in these studies does have a story to tell and the story is that a DA pharmaceutical composition, administered orally, provided a method to treat or prevent ARDS and treat SARS. Preferably, the pharmaceutical composition for daily administration comprises DA delivering a daily total dose of from about 20 mg to about 2000 mg to a human adult.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an LXH-2301 pharmaceutical composition and application of the LXH-2301 pharmaceutical composition in preparation of a medicine for treating gout with hyperuricemia. The LXH-2301 pharmaceutical composition disclosed by the invention comprises the following components: (a) LXH-2301 tablets with the specification of 0.5 g / tablet; (b) febuxostat tablets with the specification of 20 mg / tablet; wherein the LXH-2301 tablet is administered three times a day, two tablets are administered each time, the total dosage is 1.0 g, and the LXH-2301 tablet is combined with the febuxostat tablet for use. Patients suitable for the composition need to simultaneously meet the following screening standards: morning urine pHlt; and 6.0. The LXH-2301 pharmaceutical composition provided by the invention is applied to the preparation of medicines for treating gout with hyperuricemia, and the limitation of insufficient curative effect on patients with uric acid poor excretion type gout is solved; the problem of lack of prevention means for uric acid crystallization kidney injury is solved.

Disclosed in the present invention is an adjustable autoinjector, comprising: a main shaft rotatably provided in a pen body, wherein a push rod assembly is provided in the main shaft; a dose knob used for dose setting and dial-back, and configured to: during dose setting, drive the main shaft to rotate and allow for energy storage of an energy storage assembly, wherein the energy storage assembly is fitted over the main shaft; a connecting assembly provided at the lower portion the main shaft, and configured to: limit reverse rotation of the main shaft when a dose has been set, release the limitation on the reverse rotation of the main shaft when the dose knob rotates reversely due to over-setting of the dose, and be disconnected from the main shaft during injection; a dose limiting assembly provided in the dose knob and configured to prevent a set total dose from exceeding the total dose of liquid medicament; and the energy storage assembly comprising a spiral spring. In the adjustable autoinjector of the present invention, the main shaft is rotatably provided in the pen body; the energy storage assembly is provided on the main shaft; the dose knob is used for dose setting and allowing for energy storage of the energy storage assembly; during injection, the spiral spring drives the main shaft to rotate and provides torque suitable for high-viscosity liquid medicament; and when the dose is set excessively, a dial-back operation can be performed.

The present invention relates to a modified-release composition comprising orlistat and acarbose, comprising individually distinct parts with different release patterns:a) a first part, G1, comprising from about 5 to about 70% w / w of the total dose of acarbose,b) a second part, G2A, comprising from about 30 to about 95% w / w of the total dose of acarbose,c) a third part, G2B, comprising from about 10 to about 90% w / w of the total dose of orlistat, andd) a fourth part, G3, comprising from about 10 to about 80% w / w of the total dose of orlistat, and the total concentration of acarbose and orlistat, respectively, in the composition is 100% w / w.

This invention discloses a voxel-based system and method for determining the equivalent biological dose of targeted alpha nuclide therapy. The system constructs a patient-specific three-dimensional voxel anatomical model and activity distribution map through an image processing module; an intelligent source term module, based on the decay characteristics of the selected alpha nuclide, calls a pre-built dose point kernel database to generate an equivalent total dose point kernel; a dose calculation module performs rapid convolution calculation based on cumulative activity and the equivalent total dose point kernel to obtain the three-dimensional physical absorbed dose; and a biological dose module integrates a micro-dose kinetic model to convert the physical dose into a three-dimensional biological dose distribution map equivalent to conventional external beam radiotherapy. This invention overcomes the technical shortcomings of standard models, such as large errors, time-consuming Monte Carlo simulations, reliance on multi-timepoint dynamic imaging, and the inability of physical dose to reflect the biological effects of alpha particles. It achieves efficient, accurate, and clinically practical individualized biological dose assessment, significantly improving the accuracy and safety of treatment plans.

The application relates to a method for system-level total dose effect test, which is used for solving the problem that the system radiation resistance performance is difficult to be accurately evaluated in the existing system-level total dose effect test process. The specific steps of the application are as follows: step 1, placing a test system on a rotating unit in an irradiation room; step 2, calibrating and recording the front end, rear end and rear end dose rate of 180 degrees of the test system by using a dose rate calibration device; step 3, irradiating according to the dose rate calibration result of step 2; step 4, segmenting the total dose, and obtaining the total dose D' total ; step 5, calculating the first irradiation time point t'1, the second irradiation time t'2 and the total irradiation time t' of each dose segment; and step 6, combining the calculation results of steps 4 and 5, and irradiating to n segments to complete the irradiation or irradiating the test system to the target total dose value. The test steps of the application are simple and easy to operate.​​

This invention belongs to the field of animal model construction technology, specifically providing a method for constructing and using a mouse radiation dermatitis model. The method involves irradiating localized areas of healthy mice with X-rays at a dose rate of 5.128 Gy / min in fractionated doses every other day, with a total dose of 30-49 Gy, to establish a mouse radiation dermatitis model. This invention uses a fractionated X-ray irradiation mode commonly used in clinical radiotherapy, which can stably induce radiation dermatitis of varying degrees. Skin damage is significantly dependent on the irradiation dose. A total dose of 30 Gy is optimal, and after 35 days of development, a standardized model closely resembling clinical grade II radiation dermatitis can be constructed. This method is simple to operate, has good reproducibility, and a low animal mortality rate. It can realistically simulate the skin damage process of clinical radiotherapy, providing a reliable basis for research on the mechanism of radiation dermatitis and is suitable for the screening and identification of related preventive and therapeutic drugs.

Provided herein are a method of treating type 1 diabetes (T1D). In some embodiments, such method can include administering to a subject in need thereof a 12-day course of teplizumab at a total dose of more than about 9000 μg / m2.

The invention discloses an X-ray total dose determination method for an integrated circuit chip radiation effect evaluation test, and the method comprises the steps: carrying out the simulation modeling of each plate layer structure related to a radiation sensitive region in a to-be-tested integrated circuit chip, and obtaining a real structure model, simulating an X-ray irradiation environment and counting the absorbed dose of a sensitive area in the real structure model of the integrated circuit chip; performing simulation by adopting a balance model body, and layering the balance model body according to each plate layer structure of the real structure model to obtain a simulation structure model; simulating an X-ray irradiation environment and counting the absorbed dose of a sensitive area in the simulation structure model; and calculating a dose conversion factor according to the real structure model and the absorbed dose of the sensitive area of the balance die body, and correcting according to the dose conversion factor to obtain the X-ray total dose of the radiation effect evaluation test. According to the invention, the total X-ray dose is corrected through simulation calculation before the test, so that the dose accuracy in the irradiation test process can be ensured.

The present invention is directed inter alia to a modified botulinum neurotoxin A (BoNT / A) for use in treating cervical dystonia, wherein the modified BoNT / A is administered by intramuscular injection to an affected neck muscle of a subject, wherein the modified BoNT / A is administered by way of a unit dose of greater than 17,000 pg of modified BoNT / A, wherein at least a single unit dose is administered to the affected neck muscle, wherein the total dose administered during the treatment is up to 400,000 pg of modified BoNT / A, and wherein the modified BoNT / A comprises a BoNT / A light-chain and translocation domain, and a BoNT / B receptor binding domain (HC domain). Also provided are corresponding methods, uses, unit dosage forms, and kits.

The invention discloses a method for evaluating the total ionization dose resistance of a HgCdTe infrared detector. The method comprises the following steps: selecting and processing a sample; selecting an irradiation dose; irradiating a bias condition; testing parameters; annealing test; the evaluation method provided by the invention is suitable for various HgCdTe infrared detectors, can evaluate the total ionization dose resistance of the HgCdTe infrared detector for aerospace, and solves the problem of lack of evaluation methods for the total ionization dose resistance of the HgCdTe infrared detector for aerospace.

The present invention provides a modified BoNT / A for use in treating facial lines, wherein the modified BoNT / A is administered by intramuscular injection at a plurality of sites of the face of the subject, wherein the modified BoNT / A is administered by way of a unit dose of greater than 1754 pg or greater than 8000 pg) of modified BoNT / A per site, wherein the plurality of sites are selected from: up to two sites of a corrugator muscle and one site of a procerus muscle for treating glabellar lines, up to five sites of a frontalis muscle for treating forehead lines, and up to three sites of an orbicularis oculi muscle for treating lateral canthal lines, wherein the total dose of modified BoNT / A administered during the treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light-chain and translocation domain (HN domain), and a BoNT / B receptor binding domain (HC domain).